Connection
Thomas Flaig to Multicenter Studies as Topic
This is a "connection" page, showing publications Thomas Flaig has written about Multicenter Studies as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.426 |
|
|
|
-
Lam ET, Flaig TW. Prostate cancer: celecoxib trampled in the STAMPEDE trial. Nat Rev Urol. 2012 May 29; 9(7):358-60.
Score: 0.382
-
Petrylak DP, Ratta R, Gafanov R, Facchini G, Piulats JM, Kramer G, Flaig TW, Chandana SR, Li B, Burgents J, Fizazi K. KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol. 2021 Sep; 17(25):3291-3299.
Score: 0.045